Moxifloxacin Hydrochloride

Moxifloxacin Hydrochloride

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Moxifloxacin Hydrochloride
Category Antibiotics
Catalog number BBF-04614
CAS 186826-86-8
Molecular Weight 437.89
Molecular Formula C21H24FN3O4.HCl
Purity >98%

Ordering Information

Catalog Number Size Price Stock Quantity
BBF-04614 100 g $293 In stock

Online Inquiry

Add to cart

Description

Moxifloxacin exerts its effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. It is a fluoroquinolone antibiotic with broad-spectrum bactericidal activity against gram-positive and gram-negative strains.

Specification

Related CAS 192927-63-2 (monohydrate) 151096-09-2 (free base)
Synonyms BAY12-8039 HCl; BAY12 8039 HCl; BAY128039 HCl; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride (1:1); Actira; Avalox; Lapinix; Moxifloxacine Hydrochloride; Octegra
Storage Preserve in tight, light-resistant containers. Store at room temperature.
IUPAC Name 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
Canonical SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
InChI InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1
InChI Key IDIIJJHBXUESQI-DFIJPDEKSA-N
Source Synthetic

Properties

Appearance Yellow Powder
Antibiotic Activity Spectrum Gram-positive bacteria; Gram-negative bacteria
Boiling Point 636.4°C at 760 mmHg
Melting Point 324-325°C
Solubility Slightly soluble in Water, DMF, DMSO

Reference Reading

1.Potentiometric determination of moxifloxacin in some pharmaceutical formulation using PVC membrane sensors.
Hefnawy MM1, Homoda AM2, Abounassif MA1, Alanazi AM1, Al-Majed A1, Mostafa GA1. Chem Cent J. 2014 Sep 17;8(1):59. doi: 10.1186/s13065-014-0059-y. eCollection 2014.
BACKGROUND: The construction and electrochemical response characteristics of Poly (vinyl chloride) membrane sensors for moxifloxacin HCl (MOX) are described. The sensing membranes incorporate ion association complexes of moxifloxacin cation and sodium tetraphenyl borate (NaTPB) (sensor 1), phosphomolybdic acid (PMA) (sensor 2) or phosphotungstic acid (PTA) (sensor 3) as electroactive materials.
2.Risk for uveitis with oral moxifloxacin: a comparative safety study.
Eadie B1, Etminan M2, Mikelberg FS1. JAMA Ophthalmol. 2015 Jan;133(1):81-4. doi: 10.1001/jamaophthalmol.2014.3598.
IMPORTANCE: Numerous case reports have suggested that the recent use of moxifloxacin may lead to uveitis. This epidemiologic study is, to our knowledge, the first to explore the relationship between oral moxifloxacin hydrochloride use and uveitis.
3.Development and validation of sensitive kinetic spectrophotometric method for the determination of moxifloxacin antibiotic in pure and commercial tablets.
Ashour S1, Bayram R2. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Apr 5;140:216-22. doi: 10.1016/j.saa.2014.12.111. Epub 2015 Jan 3.
New, accurate, sensitive and reliable kinetic spectrophotometric method for the assay of moxifloxacin hydrochloride (MOXF) in pure form and pharmaceutical formulations has been developed. The method involves the oxidative coupling reaction of MOXF with 3-methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (MBTH) in the presence of Ce(IV) in an acidic medium to form colored product with lambda max at 623 and 660 nm. The reaction is followed spectrophotometrically by measuring the increase in absorbance at 623 nm as a function of time. The initial rate and fixed time methods were adopted for constructing the calibration curves. The linearity range was found to be 1.89-40.0 μg mL(-1) for initial rate and fixed time methods. The limit of detection for initial rate and fixed time methods is 0.644 and 0.043 μg mL(-1), respectively. Molar absorptivity for the method was found to be 0.89×10(4) L mol(-1) cm(-1). Statistical treatment of the experimental results indicates that the methods are precise and accurate.
4.Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.
Shastri DH1, Prajapati ST, Patel LD. Curr Drug Deliv. 2010 Jul;7(3):238-43.
Conventional eye drops show relatively low bioavailability due to poor precorneal contact time. In situ hydrogels are of great importance in providing sustained ocular drug delivery. By exhibiting elastic properties they resist ocular drainage of the drug leading to longer contact times. In the present study an in situ gelling thermoreversible mucoadhesive gel was formulated of an antibacterial agent, Moxifloxacin HCl using a combination of poloxamer 407 and poloxamer 188 with different mucoadhesive polymers such as Xanthan gum and Sodium alginate with a view to increase gel strength and bioadhesion force and thereby increased precorneal contact time and bioavailability of the drug. Formulations were evaluated for physical parameters like clarity, pH, spreadability, drug content, gelation temperature, gel strength, bioadhesion force and in vitro drug release study. Formulations were found transparent, uniform in consistency and had good spreadability within a pH range of 6.

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket